RET signals through focal adhesion kinase in medullary thyroid cancer cells

Ganesh R. Panta, Fiemu Nwariaku, Lawrence T. Kim

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The RET proto-oncogene is implicated in medullary thyroid cancer (MTC) and has been shown to signal indirectly to focal adhesion kinase (FAK) in cell types other than MTC. We have previously shown that FAK is phosphorylated in MTC cells. We hypothesized that inhibition of RET with pharmacologic inhibitors or by depletion with siRNA would decrease FAK phosphorylation in MTC cells, thereby implicating a RET-FAK signaling pathway. Human MTC cells (TT cells) were treated with pharmacologic inhibitors or transfected with RET siRNA. Total protein was detected by immunoblotting. Phosphorylated FAK was detected by immunoprecipitating total FAK and immunoblotting with antiphosphotyrosine. Treatment of MTC cells with the inhibitor PP2 significantly inhibited RET phosphorylation and, to a lesser extent, FAK phosphorylation. Imatinib mesylate inhibited FAK phosphorylation only at high doses. RET siRNA significantly decreased RET expression and FAK phosphorylation. RET signals through FAK in MTC cells. Whether this is due to a direct or indirect interaction is not yet clear. PP2 or a similar inhibitor might be a useful treatment for MTC.

Original languageEnglish (US)
Pages (from-to)1212-1217
Number of pages6
JournalSurgery
Volume136
Issue number6
DOIs
StatePublished - Dec 2004

Fingerprint

Focal Adhesion Protein-Tyrosine Kinases
Phosphorylation
Small Interfering RNA
Immunoblotting
Medullary Thyroid cancer
Proto-Oncogenes

ASJC Scopus subject areas

  • Surgery

Cite this

RET signals through focal adhesion kinase in medullary thyroid cancer cells. / Panta, Ganesh R.; Nwariaku, Fiemu; Kim, Lawrence T.

In: Surgery, Vol. 136, No. 6, 12.2004, p. 1212-1217.

Research output: Contribution to journalArticle

Panta, Ganesh R. ; Nwariaku, Fiemu ; Kim, Lawrence T. / RET signals through focal adhesion kinase in medullary thyroid cancer cells. In: Surgery. 2004 ; Vol. 136, No. 6. pp. 1212-1217.
@article{e9ccafaaa27b498e952976fe40222a13,
title = "RET signals through focal adhesion kinase in medullary thyroid cancer cells",
abstract = "The RET proto-oncogene is implicated in medullary thyroid cancer (MTC) and has been shown to signal indirectly to focal adhesion kinase (FAK) in cell types other than MTC. We have previously shown that FAK is phosphorylated in MTC cells. We hypothesized that inhibition of RET with pharmacologic inhibitors or by depletion with siRNA would decrease FAK phosphorylation in MTC cells, thereby implicating a RET-FAK signaling pathway. Human MTC cells (TT cells) were treated with pharmacologic inhibitors or transfected with RET siRNA. Total protein was detected by immunoblotting. Phosphorylated FAK was detected by immunoprecipitating total FAK and immunoblotting with antiphosphotyrosine. Treatment of MTC cells with the inhibitor PP2 significantly inhibited RET phosphorylation and, to a lesser extent, FAK phosphorylation. Imatinib mesylate inhibited FAK phosphorylation only at high doses. RET siRNA significantly decreased RET expression and FAK phosphorylation. RET signals through FAK in MTC cells. Whether this is due to a direct or indirect interaction is not yet clear. PP2 or a similar inhibitor might be a useful treatment for MTC.",
author = "Panta, {Ganesh R.} and Fiemu Nwariaku and Kim, {Lawrence T.}",
year = "2004",
month = "12",
doi = "10.1016/j.surg.2004.06.048",
language = "English (US)",
volume = "136",
pages = "1212--1217",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - RET signals through focal adhesion kinase in medullary thyroid cancer cells

AU - Panta, Ganesh R.

AU - Nwariaku, Fiemu

AU - Kim, Lawrence T.

PY - 2004/12

Y1 - 2004/12

N2 - The RET proto-oncogene is implicated in medullary thyroid cancer (MTC) and has been shown to signal indirectly to focal adhesion kinase (FAK) in cell types other than MTC. We have previously shown that FAK is phosphorylated in MTC cells. We hypothesized that inhibition of RET with pharmacologic inhibitors or by depletion with siRNA would decrease FAK phosphorylation in MTC cells, thereby implicating a RET-FAK signaling pathway. Human MTC cells (TT cells) were treated with pharmacologic inhibitors or transfected with RET siRNA. Total protein was detected by immunoblotting. Phosphorylated FAK was detected by immunoprecipitating total FAK and immunoblotting with antiphosphotyrosine. Treatment of MTC cells with the inhibitor PP2 significantly inhibited RET phosphorylation and, to a lesser extent, FAK phosphorylation. Imatinib mesylate inhibited FAK phosphorylation only at high doses. RET siRNA significantly decreased RET expression and FAK phosphorylation. RET signals through FAK in MTC cells. Whether this is due to a direct or indirect interaction is not yet clear. PP2 or a similar inhibitor might be a useful treatment for MTC.

AB - The RET proto-oncogene is implicated in medullary thyroid cancer (MTC) and has been shown to signal indirectly to focal adhesion kinase (FAK) in cell types other than MTC. We have previously shown that FAK is phosphorylated in MTC cells. We hypothesized that inhibition of RET with pharmacologic inhibitors or by depletion with siRNA would decrease FAK phosphorylation in MTC cells, thereby implicating a RET-FAK signaling pathway. Human MTC cells (TT cells) were treated with pharmacologic inhibitors or transfected with RET siRNA. Total protein was detected by immunoblotting. Phosphorylated FAK was detected by immunoprecipitating total FAK and immunoblotting with antiphosphotyrosine. Treatment of MTC cells with the inhibitor PP2 significantly inhibited RET phosphorylation and, to a lesser extent, FAK phosphorylation. Imatinib mesylate inhibited FAK phosphorylation only at high doses. RET siRNA significantly decreased RET expression and FAK phosphorylation. RET signals through FAK in MTC cells. Whether this is due to a direct or indirect interaction is not yet clear. PP2 or a similar inhibitor might be a useful treatment for MTC.

UR - http://www.scopus.com/inward/record.url?scp=10644242812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644242812&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2004.06.048

DO - 10.1016/j.surg.2004.06.048

M3 - Article

C2 - 15657578

AN - SCOPUS:10644242812

VL - 136

SP - 1212

EP - 1217

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -